WEBINAR: Recent Advancements in Neurodegenerative Biomarkers
Recent Advancements in Neurodegenerative Biomarkers: Progress Towards a Diagnostic Blood Test for Alzheimer’s Disease
With much enthusiasm following the research coming out of AD/PD™2021, we were pleased to bring together leading industry experts to discuss neurological advancements related to the ultra-sensitive quantification of pTau181, pTau217, pTau231, and other neurological biomarkers. This panel discussion and live Q and A covered the latest developments and opportunities to impact AD clinical trials and diagnostics.
The discussion was led by Quanterix Chairman, Chief Executive Officer, and President, Kevin Hrusovsky and featured Charlotte Teunissen, Ph.D., UMC Amsterdam, and Henrik Zetterberg, Ph.D., University of Gothenberg.
Share this page